Meta AnalysisID 74
板蓝根治疗非复杂性急性呼吸道感染：一项系统评价
CRD42018081416
This systematic review will evaluate the clinical effectiveness and safety of the herb Ban Lan Gen for uncomplicated acute respiratory tract infections (ARTIs).
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Herb: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 74
- Evidence Id
- 8632
- Core Evidence Id
- 8632
- Source Meta Analysis Id
- 68
- Herb2 Meta Analysis Id
- HBMA000068
- Crd Id
- CRD42018081416
- Title
- Ban Lan Gen for uncomplicated acute respiratory tract infections: a systematic review
- Review Question
- This systematic review will evaluate the clinical effectiveness and safety of the herb Ban Lan Gen for uncomplicated acute respiratory tract infections (ARTIs).
- Study Type Included
- This systematic review will include published and unpublished randomised controlled trials (RCTs) and quasi-RCTs. Crossover trials, controlled before and after studies, interrupted time series (ITS) studies, and non-experimental studies were not included due to their potential high risk of bias.
- Condition Being Studied
- Uncomplicated acute respiratory tract infections.
- Participant
- Trials with patients in all age groups, with either an ARTI diagnosis or appearance with symptoms of uncomplicated ARTIs. A clinical diagnosis of ARTIs was the main inclusion criteria. Diagnoses of upper or lower ARTIs include common cold, influenza, rhinosinusitis, laryngitis, tonsillitis, pharyngitis, croup, acute otitis media, and bronchitis. Symptoms of ARTIs are defined as having symptoms such as cough, sore throat, fever, runny nose and discoloured sputum for a duration of less than four weeks. Trials will be excluded if they recruited participants with asthma, pneumonia, chronic obstructive pulmonary disease (COPD), acute exacerbations of COPD, had active or previous peptic ulceration, were hypersensitive to analgesics, had psychosis, or were severely depressed. Exclusion also applied to trials that included patients who required hospital admission (for example, for meningitis, epiglottitis, or Kawasaki disease), had a known immune deficiency, or were pregnant or breastfeeding (Little et al., 2014).
- Animal
- Human Disease Modelled
- Intervention
- Any form of Ban Lan Gen, including oral, nasal, or external use, apart from injection; either as a single herb, or within a herbal remedy. There will be no limitation concerning dosage, methods of dosing or duration of administration.
- Comparator Control
- No intervention, placebo; usual care such as antipyretics, antivirals, antibiotics, anti-inflammatories, steroids or corticosteroids will be included.
- Main Outcome
- Change in reported antibiotic usage.
- Outcome Measure
- Additional Outcome
- 1). Participant self-reported or clinician/observer assessment on overall ARTI symptoms or two target symptoms cough and sore throat. Commonly used measures included: • Changes on visual analogue scales (VAS) • Changes in symptoms scored on a Likert-type scale • Global assessment of symptom improvement 2). Mean time to reported remission or resolution of overall ARTI symptoms or two target symptoms cough and sore throat. This may be measured directly, through patient or clinician/observer report or indirectly as the time to return to normal activities. 3). Adverse events (AEs): This included any anaphylactic, allergic reactions, hypersensitivity reactions, or complications of taking Ban Lan Gen. Information regarding AEs due to interactions among Ban Lan Gen in combination with other remedies, or potential interactions with medications patients had for their co-morbidities will also be collected. We defined serious AEs according to the International Council on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) guidelines as any event that leads to death, is life-threatening, requires hospitalisation or leads to persistent or significant disability; biochemistry results such as electrolytes, liver and kidney function tests (alanine aminotransferase and creatinine) (ICH, 1999).
- Study Method
- Intervention, Meta-analysis, Systematic review
- Keyword
- Acute Disease; Humans; Respiratory Tract Infections
- Contact
- Xiao-Yang Hu [email protected]
- Organisational Affiliation
- University of Southampton https://www.southampton.ac.uk
- Funding Source
- This review is funded by National Institute for Health Research (NIHR) Solent NHS Trust Research Capability Funding (RCF).
- Other Selection Criteria
- Final Publication
- Same Topic Review
- Published Protocol
- Review Type
- Language
- English
- Country
- South Korea, China, England
- Review Stage
- Review Ongoing
- First Submission Date
- 2018-01-14
- Registration Date
- 2018-01-15
- Anticipated Start Date
- 2017-11-27
- Anticipated Completion Date
- 2018-09-30
- Title Cn
- 板蓝根治疗非复杂性急性呼吸道感染：一项系统评价
- Title En
- Ban Lan Gen for uncomplicated acute respiratory tract infections: a systematic review
- Bilingual Status
- complete